Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record.

Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents

Open access
Payne, David J., Miller, William H., Berry, Valerie, Brosky, John, Burgess, Walter J., Chen, Emile, DeWolf, Walter E., Fosberry, Andrew P., Greenwood, Rebecca, Head, Martha S., Heerding, Dirk A., Janson, Cheryl A., Jaworski, Deborah D., Keller, Paul M., Manley, Peter J., Moore, Terrance D., Newlander, Kenneth A., Pearson, Stewart, Polizzi, Brian J., Qiu, Xiayang, Rittenhouse, Stephen F., Slater-Radosti, Courtney, Salyers, Kevin L., Seefeld, Mark A., Smyth, Martin G., Takata, Dennis T., Uzinskas, Irene N., Vaidya, Kalindi, Wallis, Nicola G., Winram, Scott B., Yuan, Catherine C. K., Huffman, William F.·2002·Antimicrobial Agents and Chemotherapy

Abstract

Bacterial enoyl-acyl carrier protein (ACP) reductase (FabI) catalyzes the final step in each elongation cycle of bacterial fatty acid biosynthesis and is an attractive target for the development of new antibacterial agents. High-throughput screening of the Staphylococcus aureus FabI enzyme identified a novel, weak inhibitor with no detectable antibacterial activity against S. aureus . Iterative medicinal chemistry and X-ray crystal structure-based design led to the identification of compound 4 [( E )- N -methyl- N -(2-methyl-1 H -indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide], which is 350-fold more potent than the original lead compound obtained by high-throughput screening in the FabI inhibition assay. Compound 4 has exquisite antistaphylococci activity, achieving MICs at which 90% of isolates are inhibited more than 500 times lower than those of nine currently available antibiotics against a panel of multidrug-resistant strains of S. aureus and Staphylococcus epidermidis . Furthermore, compound 4 exhibits excellent in vivo efficacy in an S. aureus infection model in rats. Biochemical and genetic approaches have confirmed that the mode of antibacterial action of compound 4 and related compounds is via inhibition of FabI. Compound 4 also exhibits weak FabK inhibitory activity, which may explain its antibacterial activity against Streptococcus pneumoniae and Enterococcus faecalis , which depend on FabK and both FabK and FabI, respectively, for their enoyl-ACP reductase function. These results show that compound 4 is representative of a new, totally synthetic series of antibacterial agents that has the potential to provide novel alternatives for the treatment of S. aureus infections that are resistant to our present armory of antibiotics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.46.10.3118-3124.2002

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 170

Metadata

Authors
Payne, D. J., Miller, W. H., Berry, V., Brosky, J., Burgess, W. J., Chen, E., DeWolf, W. E., Fosberry, A. P., Greenwood, R., Head, M. S., Heerding, D. A., Janson, C. A., Jaworski, D. D., Keller, P. M., Manley, P. J., Moore, T. D., Newlander, K. A., Pearson, S., Polizzi, B. J., Qiu, X., Rittenhouse, S. F., Slater-Radosti, C., Salyers, K. L., Seefeld, M. A., Smyth, M. G., Takata, D. T., Uzinskas, I. N., Vaidya, K., Wallis, N. G., Winram, S. B., Yuan, C. C. K., & Huffman, W. F.
Venue
Antimicrobial Agents and Chemotherapy
Published
2002-10
Volume
46
Issue
10
Pages
3118-3124
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2157638286
Cited by
170
References
0
FWCI
4.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents. https://app.cochat.ai/papers/10.1128/aac.46.10.3118-3124.2002
The paper
Payne, D. J., Miller, W. H., Berry, V., Brosky, J., Burgess, W. J., Chen, E., DeWolf, W. E., Fosberry, A. P., Greenwood, R., Head, M. S., Heerding, D. A., Janson, C. A., Jaworski, D. D., Keller, P. M., Manley, P. J., Moore, T. D., Newlander, K. A., Pearson, S., Polizzi, B. J., . . . Huffman, W. F. (2002). Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.46.10.3118-3124.2002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.